ERBB2 and endometrial serous adenocarcinoma: Although there are currently no clinical trials or case reports specifically addressing trastuzumab use in GTN, the experience with HER2-targeted therapies in other HER2-positive gynecologic malignancies, such as uterine serous carcinoma, demonstrates their clinical efficacy.